secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2022-02-03T23:59:59+00:00
Accession:  0001193125-22-025957
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology forms AAV manufacturing JV with Oxford; receives $130M; owns 20% of Newco
--------------------------------------------------------------------------------

- Homology receives $130M upfront from Oxford Biomedica; Oxford invests $50M additional into Newco.
- Post-closing OXB owns 80% and Homology 20% of Oxford Biomedica Solutions LLC.
- Tim Kelly, Homology's COO, becomes CEO and Chairman of Newco; Arthur Tzianabos on board.
- Oxford Biomedica CEO John Dawson retires; Dr. Roch Doliveux named interim CEO.
- Transaction expected to close Q1 2022, subject to HSR antitrust clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522025957/0001193125-22-025957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522025957/d306124d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-025957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer